Victor Banzon
Pulmonary Disease · Lewes, DENPI 1225073547
Payments from drug & device makers
Across 536 payments — averaging $571.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$121K
- Mallinckrodt Enterprises LLC$77K
- Mallinckrodt Hospital Products Inc.$63K
- Boehringer Ingelheim$25K
- Astrazeneca UK Limited$6K
- Intuitive Surgical$5K
- plus $9K from 31 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 158 | $121,049 |
| Mallinckrodt Enterprises LLC | 61 | $77,151 |
| Mallinckrodt Hospital Products Inc. | 94 | $63,031 |
| Boehringer Ingelheim | 41 | $24,944 |
| Astrazeneca UK Limited | 1 | $6,080 |
| Intuitive Surgical | 15 | $4,910 |
| Grifols USA, LLC | 17 | $3,941 |
| GSK | 40 | $1,155 |
| Genentech USA, Inc. | 12 | $667 |
| Jazz Pharmaceuticals Inc. | 5 | $448 |
| Sanofi | 14 | $420 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $297 |
| Bayer | 6 | $225 |
| Lilly USA, LLC | 5 | $201 |
| Harmony Biosciences LLC | 5 | $184 |
| Merck | 3 | $179 |
| Inari Medical, Inc. | 1 | $147 |
| ANI Pharmaceuticals, Inc. | 4 | $132 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Johnson & Johnson | 1 | $115 |
| AbbVie | 5 | $109 |
| Insmed, Inc. | 6 | $102 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Verona Pharma, Inc. | 5 | $86 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $84 |
| Sunovion Pharmaceuticals Inc. | 5 | $78 |
| Tactile Systems Technology Inc | 1 | $73 |
| Viatris Specialty LLC | 3 | $68 |
| Mylan Specialty L.p. | 3 | $63 |
| Novartis | 2 | $36 |
| Shire North American Group Inc | 2 | $34 |
| Philips North America LLC | 2 | $32 |
| United Therapeutics Corporation | 1 | $32 |
| Resmed Corp | 1 | $20 |
| Advanced Respiratory, Inc | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| Electromed, Inc. | 1 | $14 |
How this compares
$306,365 in reported general payments places this provider in the 95th percentile of 39 pulmonary disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Lewes
- Vikas BatraLewes$17K
- Ercilia AriasLewes$11K
- Samih RaadLewes$9K
- Omar MahmoudLewes$2K
- Hummayun IsmailNewark$206K
- Albert RizzoNewark$162K
- Michel SamahaMilford$94K
- Haroon RajaNewark$44K
- Carole GuyNewark$35K
- Ismael MatusNewark$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.